The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles